{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:34:38Z","timestamp":1769106878576,"version":"3.49.0"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Tuberculosis (TB) continues to pose a global health challenge, exacerbated by the rise of drug-resistant strains. The development of new TB therapies is an arduous and time-consuming process. To expedite the discovery of effective treatments, computational structure-based drug repurposing has emerged as a promising strategy. From this perspective, conditionally essential targets present a valuable opportunity, and the mycobactin biosynthesis pathway stands out as a prime example highlighting the intricate response of Mycobacterium tuberculosis (Mtb) to changes in iron availability. This study focuses on the repurposing and revival of FDA-approved drugs (library) as potential inhibitors of MbtA, a crucial enzyme in mycobactin biosynthesis in Mtb conserved among all species of mycobacteria. The literature suggests this pathway to be associated with drug efflux pumps, which potentially contribute to drug resistance. This makes it a potential target for antitubercular drug discovery. Herein, we utilized cheminformatics and structure-based drug repurposing approaches, viz., molecular docking, dynamics, and PCA analysis, to decode the intermolecular interactions and binding affinity of the FDA-reported molecules against MbtA. Virtual screening revealed ten molecules with significant binding affinities and interactions with MbtA. These drugs, originally designed for different therapeutic indications (four antiviral, three anticancer, one CYP450 inhibitor, one ACE inhibitor, and one leukotriene antagonist), were repurposed as potential MbtA inhibitors. Furthermore, our study explores the binding modes and interactions between these drugs and MbtA, shedding light on the structural basis of their inhibitory potential. Principal component analysis highlighted significant motions in MbtA-bound ligands, emphasizing the stability of the top protein\u2013ligand complexes (PLCs). This computational approach provides a swift and cost-effective method for identifying new MbtA inhibitors, which can subsequently undergo validation through experimental assays. This streamlined process is facilitated by the fact that these compounds are already FDA-approved and have established safety and efficacy profiles. This study has the potential to lay the groundwork for addressing the urgent global health challenge at hand, specifically in the context of combating antimicrobial resistance (AMR) and tuberculosis (TB).<\/jats:p>","DOI":"10.3390\/pathogens12121433","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T03:25:31Z","timestamp":1702265131000},"page":"1433","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors"],"prefix":"10.3390","volume":"12","author":[{"given":"Gourav","family":"Rakshit","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4871-0453","authenticated-orcid":false,"given":"Abanish","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-4153","authenticated-orcid":false,"given":"Venkatesan","family":"Jayaprakash","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/1568026621999201211200447","article-title":"Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host-Directed Therapies","volume":"21","author":"Borah","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_2","unstructured":"World Health Organization (2023, September 18). Tuberculosis: Key Facts. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fimmu.2017.00084","article-title":"Mycobacterial Dormancy Systems and Host Responses in Tuberculosis","volume":"8","author":"Peddireddy","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/acs.jmedchem.0c01176","article-title":"The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis","volume":"64","author":"Shyam","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_5","first-page":"271","article-title":"Extensively Drug-Resistant Tuberculosis in India: Current Evidence on Diagnosis & Management","volume":"145","author":"Prasad","year":"2017","journal-title":"Indian J. Med. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jgar.2017.10.006","article-title":"Drug-Resistant Mycobacterium Tuberculosis: Epidemiology and Role of Morphological Alterations","volume":"12","author":"Velayati","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11224-022-02013-y","article-title":"Tuberculosis and HIV Responses Threatened by NCOVID-19: A Situation Prompting an in Silico Investigation of Reported MbtA Inhibitors for Combined Inhibition of SARS-CoV-2 and HIV-TB Co-Infection","volume":"34","author":"Rakshit","year":"2023","journal-title":"Struct. Chem."},{"key":"ref_8","first-page":"8","article-title":"Emerging Antibiotic Resistance in Post-COVID-19 Co-Infections","volume":"8","author":"Sibi","year":"2023","journal-title":"J. Clin. Med. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pawlowski, A., Jansson, M., Sk\u00f6ld, M., Rottenberg, M.E., and K\u00e4llenius, G. (2012). Tuberculosis and HIV Co-Infection. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002464"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/17460441.2022.2077328","article-title":"Approaches for Targeting the Mycobactin Biosynthesis Pathway for Novel Anti-Tubercular Drug Discovery: Where We Stand","volume":"17","author":"Shyam","year":"2022","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/MMBR.00012-07","article-title":"Siderophore-Based Iron Acquisition and Pathogen Control","volume":"71","author":"Miethke","year":"2007","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_12","unstructured":"Quadri, L.E.N. (2008). The Mycobacterial Cell Envelope, Wiley & Sons."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-micro-090110-102851","article-title":"Molecular Mechanisms of Staphylococcus Aureus Iron Acquisition","volume":"65","author":"Hammer","year":"2011","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/jb.164.2.896-903.1985","article-title":"Isolation, Identification, and Structural Analysis of the Mycobactins of Mycobacterium Avium, Mycobacterium Intracellulare, Mycobacterium Scrofulaceum, and Mycobacterium Paratuberculosis","volume":"164","author":"Barclay","year":"1985","journal-title":"J. Bacteriol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1574-6968.1982.tb00053.x","article-title":"A Simple Method for the Production of Mycobactin, the Lipid-Soluble Siderophore, from Mycobacteria","volume":"15","author":"Hall","year":"1982","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1073\/pnas.97.3.1252","article-title":"The Salicylate-Derived Mycobactin Siderophores of Mycobacterium Tuberculosis Are Essential for Growth in Macrophages","volume":"97","author":"Rutter","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cbpa.2009.03.008","article-title":"Recent Advances in Siderophore Biosynthesis","volume":"13","author":"Barry","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/br.34.2.99-125.1970","article-title":"Mycobactins: Iron-Chelating Growth Factors from Mycobacteria","volume":"34","author":"Snow","year":"1970","journal-title":"Bacteriol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1128\/JB.00359-16","article-title":"Iron Homeostasis in Mycobacterium Tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake","volume":"198","author":"Sritharan","year":"2016","journal-title":"J. Bacteriol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wells, R.M., Jones, C.M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K.S., Sun, P., Wu, F., Tian, C., and Niederweis, M. (2013). Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium Tuberculosis. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003120"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10534-021-00292-2","article-title":"Iron Uptake and Transport by the Carboxymycobactin-Mycobactin Siderophore Machinery of Mycobacterium Tuberculosis Is Dependent on the Iron-Regulated Protein HupB","volume":"34","author":"Choudhury","year":"2021","journal-title":"BioMetals"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/JB.188.2.424-430.2006","article-title":"Identification of an ABC Transporter Required for Iron Acquisition and Virulence in Mycobacterium Tuberculosis","volume":"188","author":"Rodriguez","year":"2006","journal-title":"J. Bacteriol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/JB.00223-09","article-title":"The Mycobacterium Tuberculosis High-Affinity Iron Importer, IrtA, Contains an FAD-Binding Domain","volume":"192","author":"Ryndak","year":"2010","journal-title":"J. Bacteriol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gupta, V., Gupta, R.K., Khare, G., Salunke, D.M., and Tyagi, A.K. (2009). Crystal Structure of Bfr A from Mycobacterium Tuberculosis: Incorporation of Selenomethionine Results in Cleavage and Demetallation of Haem. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008028"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1021\/ja305180n","article-title":"The Structure of the BfrB\u2013Bfd Complex Reveals Protein\u2013Protein Interactions Enabling Iron Release from Bacterioferritin","volume":"134","author":"Yao","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.1073\/pnas.0900589106","article-title":"Mycobacterial Esx-3 Is Required for Mycobactin-Mediated Iron Acquisition","volume":"106","author":"Siegrist","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Serafini, A., Pisu, D., Pal\u00f9, G., Rodriguez, G.M., and Manganelli, R. (2013). The ESX-3 Secretion System Is Necessary for Iron and Zinc Homeostasis in Mycobacterium Tuberculosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078351"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1073\/pnas.1311402111","article-title":"Self-Poisoning of Mycobacterium Tuberculosis by Interrupting Siderophore Recycling","volume":"111","author":"Jones","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/acs.jmedchem.1c01349","article-title":"Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition","volume":"65","author":"Shyam","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.bmcl.2008.03.025","article-title":"Small Molecules with Structural Similarities to Siderophores as Novel Antimicrobials against Mycobacterium Tuberculosis and Yersinia Pestis","volume":"18","author":"Stirrett","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1016\/j.bmcl.2011.08.052","article-title":"Chemical Scaffolds with Structural Similarities to Siderophores of Nonribosomal Peptide-Polyketide Origin as Novel Antimicrobials against Mycobacterium Tuberculosis and Yersinia Pestis","volume":"21","author":"Ferreras","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2013Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","article-title":"ZINC20\u2014A Free Ultralarge-Scale Chemical Database for Ligand Discovery","volume":"60","author":"Irwin","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_36","unstructured":"Morris, G.M., Goodsell, D.S., Huey, R., Hart, W.E., Halliday, S., Belew, R., and Olson, A.J. (2001). Automated Docking of Flexible Ligands to Receptor-User Guide, Available online: https:\/\/citeseerx.ist.psu.edu\/document?repid=rep1&type=pdf&doi=e992478dcbeaec5be4850f4b9f46218306e36a4e."},{"key":"ref_37","first-page":"830","article-title":"A Simple Click by Click Protocol to Perform Docking: Autodock 4.2 Made Easy for Non-Bioinformaticians","volume":"12","author":"Rizvi","year":"2013","journal-title":"EXCLI J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: Fast, Flexible, and Free","volume":"26","author":"Lindahl","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_39","first-page":"82","article-title":"Pymol: An Open-Source Molecular Graphics Tool","volume":"40","author":"DeLano","year":"2002","journal-title":"CCP4 Newsl. Protein Crystallogr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: Multiple Ligand\u2013Protein Interaction Diagrams for Drug Discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC\u2212 a Free Database of Commercially Available Compounds for Virtual Screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_42","first-page":"1","article-title":"Open Babel: An Open Chemical Toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12120","DOI":"10.1073\/pnas.182156699","article-title":"Crystal Structure of DhbE, an Archetype for Aryl Acid Activating Domains of Modular Nonribosomal Peptide Synthetases","volume":"99","author":"May","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"22315","DOI":"10.1074\/jbc.M116.744532","article-title":"Post-Translational Acetylation of MbtA Modulates Mycobacterial Siderophore Biosynthesis","volume":"291","author":"Vergnolle","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_45","unstructured":"Schieffer, G., and Peng, I. (September, January 28). Accelerating Drug Discovery in AutoDock-GPU with Tensor Cores. Proceedings of the 29th International Conference on Parallel and Distributed Computing, Limassol, Cyprus."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/0026897021000044025","article-title":"Constant Pressure-Constant Temperature Molecular Dynamics: A Correct Constrained NPT Ensemble Using the Molecular Virial","volume":"101","author":"Kalibaeva","year":"2003","journal-title":"Mol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"David, C.C., and Jacobs, D.J. Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins. In Protein Dynamics: Methods and Protocols; Humana Press, Totowa, NJ, USA, 2014; pp. 193\u2013226.","DOI":"10.1007\/978-1-62703-658-0_11"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/prot.340170408","article-title":"Essential Dynamics of Proteins","volume":"17","author":"Amadei","year":"1993","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","article-title":"Saquinavir: A Review of Its Pharmacology and Clinical Potential in the Management of HIV Infection","volume":"52","author":"Noble","year":"1996","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: A Novel Second-Generation Proteasome Inhibitor","volume":"7","author":"Khan","year":"2011","journal-title":"Future Oncol."},{"key":"ref_52","first-page":"12","article-title":"A Review on Candesartan: Pharmacological and Pharmaceutical Profile","volume":"1","author":"Husain","year":"2011","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1592\/phco.21.17.1352.34419","article-title":"Lopinavir-ritonavir: A New Protease Inhibitor","volume":"21","author":"Mangum","year":"2001","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir: A Review of Its Use in the Management of HIV Infection","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1358\/dot.1998.34.4.472184","article-title":"Zafirlukast (Accolate)","volume":"34","author":"Chung","year":"1998","journal-title":"Drugs Today"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","article-title":"Neratinib, a Novel HER2-Targeted Tyrosine Kinase Inhibitor","volume":"16","author":"Tiwari","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Morris, G.M., and Lim-Wilby, M. (2008). Molecular Modeling of Proteins, Humana Press.","DOI":"10.1007\/978-1-59745-177-2_19"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/jm800668u","article-title":"Quantitative Three Dimensional Structure Linear Interaction Energy Model of 5\u2032-O-[N-(Salicyl) Sulfamoyl] Adenosine and the Aryl Acid Adenylating Enzyme MbtA","volume":"51","author":"Labello","year":"2008","journal-title":"J. Med. Chem."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/12\/1433\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:01Z","timestamp":1760132161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/12\/1433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["pathogens12121433"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12121433","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]}}}